Montagu enters exclusive negotiations to acquire IMV Technologies

Montagu

Montagu enters exclusive negotiations with Qualium Investissement to acquire IMV Technologies

Montagu, announces today that it has entered exclusive negotiations with Qualium Investissement and management to acquire IMV Technologies.

Based in Normandy, France, IMV Technologies is the world leader in the design, manufacture, distribution and service of equipment and supplies used in animal reproduction and animal reproductive and clinical imaging. Its Life Sciences division features products used in human medical research and assisted reproduction. With operations in France, Brazil, China, India, the Netherlands, Russia, South Africa, the United Kingdom and the United States, and a vast network of distributors across more than 120 countries, IMV Technologies generates more than 85% of its revenue internationally.

IMV Technologies’ management team, supported by Qualium Investissement, has considerably grown the business through seven acquisitions and continued investments in R&D, which have allowed it to broaden its expertise and strengthen its global leadership in animal artificial insemination.

 

Alain de Lambilly, CEO of IMV Technologies, said: “We are delighted to be partnering with Montagu and see considerable opportunity ahead. The firm’s deep expertise in the healthcare and technology sectors will be a major asset for our company. Montagu’s partnership will enable us to further develop the company through significant investments in research and innovation. IMV Technologies thanks Qualium Investissement for bringing us to this place in our journey.”

Guillaume Jabalot, Director at Montagu, said: “The management team has accelerated growth and innovation at IMV Technologies, reinforced its leadership position globally and opened new growth avenues. The company operates in markets offering both long-term growth prospects and resilience, two core features of Montagu’s investment strategy. We are delighted to be partnering with management and supporting them in their growth strategy, both in France and internationally. With our backing, IMV Technologies will be able to continue its success as a consolidation platform in an industry which remains fragmented.”

Jacques Pancrazi, Partner of Qualium Investissement, said: “We are delighted to have supported IMV’s management team in its growth journey over the past six years. Continuing the work accomplished during Gilles de Robert’s 15-year leadership, Alain de Lambilly and his team have explored new avenues of growth through continued investment in innovation. This consistent focus on offering high value-added solutions to customers should further accelerate the company’s growth over the coming years.”

The transaction is subject to the final and definitive agreement between the parties and customary conditions and provisions.

Categories: News

Tags:

Prescient Healthcare Group to partner with Bridgepoint Development Capital

Bridgepoint

LONDON, January 21, 2021: Prescient Healthcare Group (Prescient), a global product strategy advisory firm serving the pharmaceutical and biotech industries, announced today that Bridgepoint Development Capital, part of Bridgepoint, the international alternative asset management group, has agreed to invest in the business for an undisclosed sum, replacing current investor Baird Capital as the majority shareholder.

 

Founded in 2007, Prescient is headquartered in London and has offices in the US, India and China. The business provides product strategy services to help its clients make better clinical and commercial decisions, resulting in enhanced outcomes for patients. Prescient works with many of the leading multinational pharmaceutical companies, as well as a growing number of emerging biotech and specialty pharmaceutical organizations. Prescient has formed a partnership with Bridgepoint to support the continued scaling of its talent platform, client value proposition and global infrastructure.

 

“We are thrilled to be partnering with Bridgepoint, which has an impressive track record supporting the scaling of people-based businesses. Bridgepoint buys into our mission of becoming the biopharma strategy partner most respected for its people, expertise and impact,” said Jamie Denison-Pender, Prescient CEO. “I’m excited by the collaborative approach and hunger for excellence that Bridgepoint will bring to the boardroom and much look forward to our partnership as we continue to invest in our passion for helping our amazing clients develop and commercialize innovative treatments that bring such hope and relief to patients globally.”

 

“We’re delighted to partner with Prescient to help it drive growth and consolidate its market leadership and share management’s ambitions for the expansion of the Prescient platform. This will be achieved through a combination of investment to enhance scale and expertise, organic growth and selective M&A, with the aim of becoming the leading technology- and data-enabled strategic product partner of choice for decision support and advisory services to the large pharma industry,” said Stephen Bonnard, partner at Bridgepoint Development Capital.

 

Dr. Nick Edwards will remain Prescient’s Chairman. Baird Capital will be reinvesting in the company as a minority shareholder alongside Bridgepoint.

Categories: News

Tags:

Priveq – new growth partner to Swemac

Priveq

Swemac Innovation AB (“Swemac”), a developer of innovative solutions for fracture treatment and joint replacement with a focus on hips and upper extremities, welcomes Priveq Investment (“Priveq”) as new minority owner to support the company in its accelerated growth strategy. The Hansson family will continue as majority owners in the company.

Swemac was founded in 1985 as a spin-off from Saab Combitech, from which the Hansson family acquired the medical implant division in 1997. Since the foundation, Swemac has grown within a unique and innovative environment, where new products continuously have been developed. Swemac has exhibited strong growth and profitability historically, and by partnering with Priveq the intention is to accelerate growth even further.

Today Swemac has an extensive product portfolio that are protected by several patents. The products are marketed in Scandinavia and Japan as well as numerous international markets. The group currently has approximately 80 employees with its head office in Linköping and a turnover of around SEK 240m.

“We are highly impressed of Swemac’s innovative spirit and commitment to deliver qualitative products that add value to clients and health care professionals. Swemac’s position is a strong foundation for continued expansion and we are looking forward to be working with the owners and management on this journey going forward”, says Senai Ayob, Partner and Investment manager at Priveq.

“Over the years, Swemac has developed into a strong and broad supplier of products and services to the orthopaedic sector. Our product portfolio is highly innovative and with Priveq as a partner, we will be able to accelerate our growth further, both in terms of new product launches but also in terms of entering new markets. The experience and competence found in Priveq appeals to me“, says Martin Sjögren, CEO at Swemac.

For more information, please contact:

Senai Ayob, Partner Priveq
+46 70 459 23 61
senai.ayob@priveq.se

Martin Sjögren, CEO Swemac Innovation AB
+46 70 915 16 95
martin.sjogren@swemac.com

About Swemac
We strive continuously to provide the market with innovative and practical solutions for fracture treatment and joint replacement to benefit patients and health care professionals. Swemac has evolved over the years within a highly innovative environment where quality has always been critical to development and production. This strong tradition of innovation and high quality remains a core characteristic and guiding compass for Swemac today. The products are currently sold via Swemac’s own sales organization in Scandinavia and through distributors on international markets. Also 3rd party brands within trauma treatment and medical imaging are distributed by Swemac in Scandinavia. The company is headquartered in Linköping and has ca 80 employees.

Visit www.swemac.com for more information.

Categories: News

Tags:

Acacia Pharma wins BEL Company of the Year for the second consecutive year

GIlde Healthcare

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.

Cambridge (United Kingdom) and Utrecht (the Netherlands) – Acacia Pharma Group plc (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy, announces that it has been awarded BEL Small Company of the Year 2020 by Euronext Brussels at its annual New Year’s Ceremony held virtually last night. This is the second consecutive year that Acacia Pharma has won this award.

“We are delighted to be recognized again with this award. 2020 has been a very successful year for Acacia Pharma, having gained approval for two new products in the US: BARHEMSYS®, a new antiemetic for surgical patients to treat post-operative nausea & vomiting, and BYFAVO™, a rapid acting and reversible sedative for patients requiring moderate sedation to undergo short medical procedures. We launched BARHEMSYS in August and are in the very final stages of the launch process for BYFAVO, which we expect to complete imminently,” commented Mike Bolinder, CEO of Acacia Pharma.

Mr. Bolinder added: “Looking to the future, our strategy is to drive the sales of both products in the US through our own organization and we believe we are well positioned for success. This potential success has been recognized in the recent initiation of coverage of the company by the healthcare analysts at Jefferies, who included Acacia Pharma as one of their top European biopharma/biotech investment ideas for 2021. We are pleased with the progress we have been able to make during the last year, especially given the impact of the global Covid-19 pandemic during the same period.”

The annual New Year’s Ceremony recognizes the best performing companies on Euronext Brussels. The BEL Small Company of the Year is awarded to a company that has demonstrated the highest relative increase in market capitalization, within the BEL Small index in 2020. The award was announced by the CEO of Euronext Brussels, Vincent Van Dessel, in the presence of Vincent Van Peteghem, Belgian Deputy Prime Minister and Minister of Finance.

Contacts

Acacia Pharma Group plc
Mike Bolinder, CEO
Gary Gemignani, CFO
+44 1223 919760 / +1 317 505 1280
IR@acaciapharma.com

International Media
Mark Swallow, Frazer Hall, David Dible
Citigate Dewe Rogerson
+44 20 7638 9571
acaciapharma@citigatedewerogerson.com

US Investors
LifeSci Advisors
Irina Koffler
+1 917-734-7387
ikoffler@lifesciadvisors.com

Media in Belgium and the Netherlands
Chris Van Raemdonck
+32 499 58 55 31
chrisvanraemdonck@telenet.be

About Acacia Pharma

Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer chemotherapy. The Company has identified important and commercially attractive unmet needs in these areas that its product portfolio aims to address.

Acacia Pharma’s first product, BARHEMSYS® (amisulpride injection) is available in the US for the management of postoperative nausea & vomiting (PONV).

BYFAVO™ (remimazolam) for injection, a very rapid onset/offset IV benzodiazepine sedative is approved in the US for use during invasive medical procedures in adults lasting 30 minutes or less, such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion UK Limited for the US market.

APD403 (intravenous and oral amisulpride), a selective dopamine antagonist for chemotherapy induced nausea & vomiting (CINV) has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy.

Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D operations are centred in Cambridge, UK. The Company is listed on the Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker symbol ACPH. For more information, visit the company’s website at www.acaciapharma.com.

About Gilde Healthcare

Gilde Healthcare is a specialized healthcare investor managing over $1.5 billion across two fund strategies: Venture & Growth and Private Equity.

Gilde Healthcare Venture & Growth invests in fast growing companies active in digital health, MedTech and therapeutics. The Venture & Growth companies are based in Europe and North America.

Gilde Healthcare Private Equity participates in profitable European lower mid-market healthcare companies with a prime focus on the Benelux and DACH region. The Private Equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market.

For more information, visit the company’s website at www.gildehealthcare.com.

Forward looking statements

This announcement includes forward-looking statements, which are based on current expectations and projections about future events. These statements may include, without limitation, any statements preceded by, followed by or including words such as “believe”, “expect”, “intend”, “may”, “plan”, “will”, “should”, “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements may and often do differ materially from actual results. These forward-looking statements are subject to risks, uncertainties and assumptions about the Company and its subsidiaries and investments, including, among other things, the development of its business, trends in its operating industry, and future capital expenditures and acquisitions. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances. Any forward-looking statements reflect the Company’s current view with respect to future events and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to the Group’s business, results of operations, financial position, prospects, growth or strategies and the industry in which it operates. Save as required by law or applicable regulation, the Company and its affiliates expressly disclaim any obligation or undertaking to update, review or revise any forward-looking statement contained in this announcement whether as a result of new information, future developments or otherwise. Forward-looking statements speak only as of the date they are made.

Categories: News

Tags:

RAD-x adds Radiologisches Zentrum Lahnstein (RZL) to its group

GIlde Healthcare

Utrecht (the Netherlands) – RAD-x is welcoming Radiologisches Zentrum Lahnstein (“RZL”) in its group.

Radiologisches Zentrum Lahnstein is a provider of diagnostic imaging services in the region Koblenz, Germany. Its three radiologists and almost 30 staff serve the community in and around Lahnstein and provide imaging services to several local hospitals.

RAD-x is pleased to see its Partnership model confirmed by the integration of RZL and expects to further accelerate the growth of its platform structure in 2021.

 

About Gilde Healthcare

Gilde Healthcare is a specialized healthcare investor managing over $1.5 billion across two fund strategies: venture & growth capital and private equity. Gilde Healthcare’s venture & growth capital fund invests in fast growing companies active in digital health, MedTech and therapeutics. The venture & growth companies are based in Europe and North America. For more information, visit the company’s website at www.gildehealthcare.com.

Categories: News

Tags:

Capsule Technologies To Be Acquired by Philips

Franciso Partners

Francisco Partners, a leading global investment firm that specializes in partnering with technology and healthcare businesses, announced today the pending sale of Capsule Technologies, Inc. (“Capsule”) to Royal Philips (“Philips”) for $635 million in cash consideration.

Francisco Partners’ investment in Capsule helped support the company’s growth and expansion across medical device integration, patient monitoring, and clinical surveillance solutions. Founded in 1997, the company has grown to serve over 2,800 hospitals and healthcare organizations in 40 countries, impacting over 20 million patients annually.

“It has been a pleasure to partner with Capsule’s management team to help grow this important business,” said Chris Adams, Partner at Francisco Partners. “Capsule is a key enabler of the digital hospital, and we have been especially proud of how impactful it has been in supporting global healthcare organizations with the challenges of COVID-19. The team has delivered exceptional growth through constant customer focus and high-quality service.”

Justin Chen, Principal at Francisco Partners, added, “We are thrilled to have helped the Capsule team build their business. They have been at the forefront of delivering mission critical and innovative healthcare solutions to liberate medical data and improve patient safety. The company is in a tremendous position, and we wish the team continued success as a part of Philips.”

Hemant Goel, CEO of Capsule, said, “Francisco Partners has been a supportive strategic partner over the past few years. Their team has been invaluable, executing on the carveout, providing thought leadership, and investing into the business to help us grow rapidly and build an enduring and strategic position. We are very proud of what the entire Capsule organization and employees have been able to accomplish together. We are excited to join Philips and continue our mission of empowering clinicians with simplified workflows and timely, actionable insights.”

Philips and Capsule are long-term partners jointly offering solutions to healthcare organizations globally. The companies share similar values and ambition to improve patient outcomes. The pending acquisition by Philips will allow both companies to enhance the value they provide to their customers and patients. The transaction is subject to certain closing conditions, including regulatory clearances in relevant jurisdictions outside of the U.S., and is expected to be completed in the first quarter of 2021. The company with its leadership team and approximately 300 employees will become part of Philips’ Connected Care segment.

Barclays served as financial advisor and Kirkland & Ellis LLP served as legal advisor to Capsule Technologies.

About Capsule Technologies

Capsule Technologies is a leading global provider of medical data technologies for hospitals and healthcare organizations. Our Medical Device Information Platform — comprised of device integration, vital signs monitoring, and clinical surveillance solutions — captures streaming clinical data from connected systems and transforms it into context-rich information for clinical documentation, alarm management, patient surveillance, decision support, predictive analytics, clinical research and more. End-to-end data management and connectivity supports better collaboration and communication between clinicians and departments. More than 2,800 global clients leverage our platform to improve patient safety, simplify workflows and raise overall satisfaction throughout the hospital and across care settings. Learn more at www.capsuletech.com.

About Francisco Partners

Francisco Partners is a leading global investment firm that specializes in partnering with technology and technology-enabled businesses. Since its launch more than 20 years ago, Francisco Partners has raised over $24 billion in committed capital and invested in more than 300 technology companies, making it one of the most active and longstanding investors in the technology industry. The firm invests in opportunities where its deep sectoral knowledge and operational expertise can help companies realize their full potential. For more information on Francisco Partners, please visit www.franciscopartners.com.

Categories: News

Tags:

Forbion invests USD 2.3M in seed financing of CoviCept Therapeutics, Inc.

Forbion

in company news

Proceeds used to develop small molecule inhibitor of SARS-CoV-2 and other RNA viruses

Naarden, The Netherlands, and Munich, Germany, January 19 2021 – Forbion, a leading European life sciences venture capital firm, today announces a $2.3m seed investment in newly formed CoviCept Therapeutics, Inc. (“CoviCept”), a California-based company that is developing a small molecule that inhibits the replication of SARS-CoV-2 (COVID-19) and other RNA viruses.

CoviCept’s lead molecule has a unique mechanism of action that is based on interference of a host cell protein and is therefore expected to have a low risk of viral resistance. It has been demonstrated to inhibit SARS-CoV-2 replication in a relevant mammalian model at a clinically relevant dose. A manufacturing process for the lead compound has been established and it has demonstrated good bioavailability and safety in humans in phase 1 studies.

CoviCept was founded by Sam Tsimikas, Philip Gordts and Jeffrey Esko, all from the University of California San Diego. The Company’s aim is to initiate a first clinical study in the second half of 2021.

Professor Tsimikas, Co-Founder, Chairman and Chief Executive Officer of CoviCept, commented: “We are pleased that Forbion has invested in us to support our continued development of a much-needed direct therapeutic option to the COVID-19 pandemic, and other RNA viruses. Forbion will provide the necessary financial and management support to allow the Company to achieve Phase 2 proof of concept data. Forbion’s track record and expertise in supporting the development of early-stage companies make them the ideal partner for CoviCept.”

Sander van Deventer, Operating Partner of Forbion, added: “Our investment in CoviCept is an example of Forbion’s commitment to responsible drug development. RNA viruses such as SARS-CoV-2, SARS-CoV-1, MERS-CoV, Ebola, Dengue, Chikungunya and Zika are the most likely cause of future pandemics. A small molecule like CoviCept’s, that can be stockpiled to be immediately available and that could be used in multiple viruses, is of enormous benefit to global health.”

The board of directors of CoviCept will comprise Sam Tsimikas, Philip Gordts, Jeffrey Esko and Sander van Deventer (Forbion).

-Ends-

For more information please contact:
Forbion contact:
Sander van Deventer, Operating Partner
P: +31 (0) 35 699 30 00

Instinctif Partners for Forbion
Melanie Toyne-Sewell/Phillip Marriage
Email: forbion@instinctif.com
P: +44 (0)207 457 2020

Notes to Editors

About Forbion
Forbion is a dedicated life sciences venture capital firm with offices in The Netherlands, Germany and Singapore. Forbion invests in life sciences companies that are active in the (bio-) pharmaceutical space.
Forbion manages well over EUR 1.7 billion across multiple fund strategies that cover all stages of (bio)pharmaceutical drug development. Forbion’s current team consists of 20 life sciences investment professionals that have built an impressive performance track record since the late nineties with successful investments in over 69 companies.

The firm is a signatory to the United Nations Principles for Responsible Investment. Besides financial objectives, Forbion selects investments that will positively affect the health and well-being of patients.
Its investors include the EIF, through its European Recovery Programme (ERP), LfA, Dutch Venture Initiative (DVI), AMUF and EFSI facilities and KfW Capital through the Programme, “ERP – Venture Capital Fonds investments”. Forbion operates a joint venture with BGV, the manager of seed and early-stage funds, especially focused on Benelux and Germany.

For more information, please visit: www.forbion.com.

About CoviCept Therapeutics, Inc.
CoviCept Therapeutics, Inc. is a newly founded company based in San Diego, USA, focused on the development of a small molecule that inhibits the replication and spread of RNA viruses, including SARS-Cov-2.

CoviCept’s lead program
CoviCept is developing a small molecule that targets a host protein that is critical for RNA viral replication and that has shown efficacy in a preclinical model of SARS-CoV-2 infection, and in cell cultures infected with various RNA viruses including Zika and Dengue. The lead molecule has shown good tolerability, availability and biodistribution in humans.

RNA viruses and pandemics
RNA viruses such as SARS-CoV-1 (“COVID”), SARS-CoV-2 (“SARS”), MERS-CoV (“MERS”), Dengue, Chikungunya, Zika and Ebola, are considered to be the most likely causes of devastating global pandemics. Vaccination strategies can prevent the spread of these viruses and protect individuals but require a significant lead time before implementation and showing efficacy. Hence, a small molecule that can be stockpiled and used to inhibit viral replication of these viruses would be an integral component of the response to pandemics caused by RNA viruses.

Categories: News

Tags:

Forbion portfolio company, NewAmsterdam Pharma completes €160M Series A Funding for Phase 3 Development Program

Forbion

in portfolio news

  • Founding investor Forbion joined by co-lead investors, Morningside Ventures and Ascendant BioCapital, and other leaders in global biopharmaceutical investment
  • Funding will support initiation and finalization of Phase 3 development of obicetrapib, a potent ApoB and LDL-c lowering small molecule drug, intended for patients not well-controlled on statins
  • Earlier seed funding of €20M was provided by Forbion and Founders

Naarden, the Netherlands, and Munich, Germany, January 14 2021 – Forbion, a leading European life sciences venture capital firm, today announces that its portfolio company, NewAmsterdam Pharma (NAP), a clinical stage company focused on the research and development of transformative therapies for cardio-metabolic diseases, has completed an oversubscribed €160M ($196M) Series A funding round.

The financing will support the full Phase 3 development of its ApoB and LDL-c lowering small molecule drug, obicetrapib. The drug, a cholesteryl ester transfer protein (CETP) inhibitor, is being developed for patients who are not well-controlled on statins.

Forbion, NAP’s founding investor, was joined by Morningside Ventures and Ascendant BioCapital as co-lead investors in the Series A financing. Also participating in this funding round were Kaiser Foundation Hospitals, BVF Partners L.P., Population Health Partners, LSP Dementia Fund, Peter Thiel, Janus Henderson Investors, Medpace, GL Capital, JVC Investment Partners, and Presight Capital.

“This is an important milestone in the advancement of obicetrapib and the growth of NewAmsterdam Pharma,” said Michael Davidson, MD, Chief Executive Officer of NewAmsterdam Pharma. “The tremendous support of our investors allows us to initiate a large, Phase 3 development program as we work to create a new option for the millions of high cardiovascular risks patients globally who, despite maximally tolerated statin therapy, require additional LDL-c lowering options.”

“Effectively inhibiting CETP to reduce atherosclerotic risk in patients is something Dr. Davidson and I have been endeavoring to achieve in our field of research for more than two decades,” said John Kastelein, MD, PhD, FESC, chief scientific officer of NewAmsterdam Pharma. “Long term follow up from the 2017 REVEAL study validated CETP as a target to lower LDL-c and reduce major adverse cardiac events (MACE).1 We believe that in obicetrapib, based on clinical studies to date, we have a molecule which is well tolerated and has not shown any of the safety issues of previous CETP inhibitors. Furthermore, based on the surrogate endpoints of the REVEAL study, obicetrapib was shown to be more effective at lowering LDL-c at a 5 mg dose in comparison to a 100 mg dose of anacetrapib.”

Sander Slootweg, Managing Partner at Forbion, said: “We are pleased to see NewAmsterdam Pharma raise such an impressive Series A round so soon after its formation, and we welcome the new investor syndicate on board. This raise will allow NAP’s seasoned management team to deliver a full Phase 3 development program for obicetrapib, exploring its potential in addressing the huge and poorly served patient population at risk of cardiovascular disease who are not well-controlled on statins.”

Two Phase 2b clinical trials for obicetrapib are underway with targeted completion in Q2 2021.
NAP is looking to initiate Phase 3 clinical trials towards the end of this year.

1. https://clinicaltrials.gov/ct2/show/study/NCT01252953

Categories: News

Tags:

CareMetx, General Atlantic and The Vistria Group Announce Strategic Growth Partnership

General Atlantic

Significant investment from General Atlantic and The Vistria Group positions CareMetx for continued growth in supporting patient access to innovative therapies

CareMetx (or the “Company”), a leading technology-enabled hub services company improving patient access to specialty medications, General Atlantic, a global growth equity firm, and The Vistria Group, a Chicago-based private investment firm, today announced a strategic partnership to further accelerate the Company’s growth. With the transaction, General Atlantic will become the majority owner of CareMetx. The Vistria Group, existing majority shareholder in CareMetx since 2017, will maintain a significant position in the Company by reinvesting through Vistria Fund III, LP. Additionally, Marty Nesbitt, Co-CEO of The Vistria Group, will serve as the Chairman of the Company.

Co-founded in 2011 by Bob Dresing and Mark Hansan, hub services pioneers, CareMetx is leading the transformation of the industry from traditional call center services to a “Digital Hub” which integrates the Company’s proprietary technology platform with award-winning patient and provider support. CareMetx works on behalf of pharmaceutical and biotechnology companies to help patients and providers navigate reimbursement complexities and will continue to launch new products intended to lower the cost burden for patients on high-cost therapies.

Mark Hansan, President and CEO of CareMetx, said, “With patients continuing to face obstacles, we are excited to have the combined capabilities of General Atlantic and Vistria behind our efforts to scale our platform, invest in our team and bring new capabilities to our clients.”

“CareMetx is a disruptor in pharma commercialization services, differentiated by its focus on leveraging technology and grounded in its commitment to helping patients,” commented Justin Sunshine, Managing Director at General Atlantic. “CareMetx plays a critical role to ensure specialty therapeutics effectively reach the patients who need them, and we look forward to working with Mark and the CareMetx team to further accelerate the Company’s growth.”

“Over the last three years of our partnership, CareMetx has demonstrated its commitment to rethinking and reinventing traditional approaches to hub services,” continued Jon Maschmeyer, Partner at The Vistria Group. “We are proud to continue supporting CareMetx’s growth and welcome the new partnership with General Atlantic.”

“We are honored Vistria has decided to reinvest in CareMetx,” Hansan added. “They have been an outstanding partner that backed two important acquisitions and accelerated our development of new products and services. Now with General Atlantic as a partner, we are confident their years of investment across the healthcare ecosystem will help scale our delivery of real-time transaction processing and services to physician practices struggling to overcome barriers for patients.”

Terms of the deal were not disclosed. The Company was advised by Baird and North Point Advisors.

About CareMetx

CareMetx, LLC is a leading technology-enabled hub services platform facilitating patient access to specialty medications. Serving pharmaceutical, biotechnology and device manufacturers, CareMetx leverages digital eServices integrated in a cohesive platform to promote efficiency in the healthcare ecosystem and remove barriers for patients and providers. CareMetx is committed to delivering compassionate advocacy to patients, decision-making data and confidence-building insight to manufacturer clients. Headquartered in Bethesda, Maryland and with over 600 employees, CareMetx serves more than 80 brands. Learn more at www.caremetx.com.

About General Atlantic

General Atlantic is a leading global growth equity firm providing capital and strategic support for growth companies. Established in 1980, General Atlantic combines a collaborative global approach, sector specific expertise, a long-term investment horizon and a deep understanding of growth drivers to partner with great entrepreneurs and management teams to build market-leading businesses worldwide. General Atlantic has more than 175 investment professionals based in New York, Amsterdam, Beijing, Greenwich, Hong Kong, Jakarta, London, Mexico City, Mumbai, Munich, Palo Alto, São Paulo, Shanghai and Singapore. For more information on General Atlantic, please visit the website: www.generalatlantic.com.

About The Vistria Group

The Vistria Group is a Chicago-based private investment firm focused on investing in middle market companies in the healthcare, education, and financial services sectors. Vistria’s team is comprised of highly experienced operating partners and private equity executives with proven track records of working with management teams in building innovative, market-leading companies. For more information, please visit www.vistria.com.

Media Contacts

Mary Armstrong & Emily Japlon
General Atlantic media@generalatlantic.com

Beth Dresing
CareMetx edresing@caremetx.com

Kevin Sajdak
The Vistria Group ks@respublicagroup.com

Categories: News

Tags:

Ardian and BNP Paribas developpement invest in Proteor, a french leader in external orthopedics

Ardian

13 January 2021 GrowthFrance, Paris

Paris, January 13, 2021 – Proteor, a major player in the manufacture and distribution of prosthetics and orthotics, has chosen to partner with Ardian, a world leading private investment house, and BNP Paribas Développement, the investment arm of BNP Paribas Group.

Through this investment, Ardian and BNP will support the company in the next phase of its development and in the acceleration of its international expansion, particularly in Europe and North America.

Founded more than 100 years ago, Proteor is a family business headquartered in Dijon, Burgundy, France. The company’s core business is in the manufacturing and distribution of orthopedic devices, with the Group providing tailor-made equipment to meet the needs of patients. Proteor employs more than 900 people and generates more than 20% of its turnover abroad, with operations in France, Europe, the United-States, China and Japan.

Proteor’s growth has been possible thanks to a network of more than 70 orthopedic centers in France and across Europe, which are staffed by more than 200 orthopedic professionals.

The company is also active in the design, manufacturing and marketing of components and materials for prosthetics and orthotics. Proteor has sites in Seurre, France and a factory in Tempe, Arizona in the US. The Group is actively engaged in innovation in this field and has filed more than 100 patents since its creation.

The Group has been focused on expansion in recent years. In 2016, it acquired Lecante, a network of orthopedic centers in France, to extend its market coverage and acquire new software expertise for orthoprosthesists), and made a first acquisition in the United-States in. In 2018, Proteor acquired Ability Dynamicswhich enabled it to expand its product offering and strengthen its presence in the US market.

Now, with the backing of Ardian and BNP Paribas Développement, Proteor will be able to accelerate its international expansion by acquiring Freedom Innovation in the US from Otto Bock Healthcare North America. This transaction is in line with Proteor’s long-term strategy and will help further strengthen its components and materials division, its production capacity and its technological know-how, particularly in microprocessor-controlled knees and new-generation ankle and foot prosthetics.

“Ardian and BNP Paribas Développement were instrumental in negotiating and securing the Freedom Innovations acquisition. With their help, we were also able to complete this first capital opening alongside the founding family. This marks the first step in a collaboration that aims to make Proteor one of the world leaders in external orthotics. » said Jean-Fraçois Cantero and Edouard Archambeaud for Proteor.

“Proteor is a French flagship in external orthopedics, which has been able to expand thanks to innovative solutions particularly adapted to patients’ needs. We are pleased to be partnering with the company in this new phase of international development and consolidation of its technological assets and help Proteor become one of the world leaders in its market”, continued Alexis Saada and Frédéric Quéru for Ardian Growth.

“This partnership reinforces a long-standing relationship based on trust with the management and the founding family. We are delighted to support Proteor in pursuing its innovation strategy and in its new phase of international growth.” concluded Gilles Poncet and Guillaume Wolf for BNP Paribas Développement.

 

ABOUT PROTEOR

Proteor is an independent family business, founded over 100 years ago and headquartered in Dijon, France. Proteor operates in the orthotics and prosthetics market with three main business areas: software, components and custom orthopedic devices. Thanks to continuous investments in innovation, numerous medical and scientific partnerships, and daily cooperation with orthoptists, Proteor benefits from recognized expertise in the orthopedic sector.

 

ABOUT ARDIAN

Ardian is a world-leading private investment house with assets of US$103bn managed or advised in Europe, the Americas and Asia. The company is majority-owned by its employees. It keeps entrepreneurship at its heart and focuses on delivering excellent investment performance to its global investor base.
Through its commitment to shared outcomes for all stakeholders, Ardian’s activities fuel individual, corporate and economic growth around the world.
Holding close its core values of excellence, loyalty and entrepreneurship, Ardian maintains a truly global network, with more than 700 employees working from fifteen offices across Europe (Frankfurt, Jersey, London, Luxembourg, Madrid, Milan, Paris and Zurich), the Americas (New York, San Francisco and Santiago) and Asia (Beijing, Singapore, Tokyo and Seoul). It manages funds on behalf of around 1,000 clients through five pillars of investment expertise: Fund of Funds, Direct Funds, Infrastructure, Real Estate and Private Debt.
Follow Ardian on Twitter @Ardian

 

ABOUT BNP PARIBAS DEVELOPPEMENT

BNP Paribas Développement, an independent subsidiary of the international banking group BNP Paribas, is a public limited company that has been investing its equity capital directly as a minority shareholder for over 30 years to support the development of high-performance SMEs and ETIs and ensure their sustainability by facilitating their transfer. In addition to the financial resources made available to the company to ensure stable resources, the vocation of BNP Paribas Développement is to support the management team over the long term in carrying out its medium-term strategic projects. Our minority position ensures our partners an adapted governance without interference in the day-to-day management, while benefiting from the strength of a recognized group and the experience of a partner with a portfolio of more than 400 diversified investments.

Participants

  • Ardian

    • Alexis Saada, Frédéric Quéru, Louise Gros
  • Proteor

    • Edouard Archambeaud, Jean-François Cantero
    • M&A advisors: Neuflize OBC (Johanna Guzman, Géraldine Grossiord, Anne Nguyen)
    • Legal advisors: Alcya Conseil (Laurent Simon, Antonin Thel, Jérôme Loisy)
    • Financial advisor: Advance (Olivier Poncin, Arnaud Vergnole, Thomas Recipon, Mehdi Adyel)
  • BNP Paribas Development

    • Gilles Poncet, Guillaume Wolf, Julien Lemaire
    • Legal advisors & audit: McDermott Will & Emery (Diana Hund, Antoine Vergnat, Emmanuelle Turek, Côme de Saint-Vincent, Katya Ascher)
    • Financial audit: Eight Advisory (Christophe Delas, Nicolas Bassi)
    • Arranger: BECM-CIC (Aurélie Stassinet, Nathalie Picard, Corinne Bugaut)
    • BNP Paribas (Stéphanie Bibollet, Antoine de la Taille), LCL (Anne Garrot, Dirk Weinand, Aurélia Bojmal), Banque Populaire BFC (Edwige Lemarchand, Christine Velon, Fabienne Blanc Mondiere)
    • Crédit Agricole (Barbara Kieres Balko, Jean-Christophe Risold, Adrien Bagard)
    • Advisor : De Gaulle, Fleurance & Associés (May Jarjour, Margaux Baratte, Vahan Guevorkian)

PRESS CONTACTS

ARDIAN – Headland

VIKTOR TSVETANOV

VTsvetanov@headlandconsultancy.co.uk +44 207 3435 7469

 

Categories: News

Tags: